ALG1L2

Across TCGA pan-cancer cohorts, ALG1L2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ALG1L2 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ALG1L2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ALG1L2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, SKCM, and COAD are the cancer types where ALG1L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	1.000	0.436	.012	22	view →
SKCM	OS	Median	All	0.338	0.784	.005	13	view →
COAD	OS	Median	All	0.111	0.871	<.001	12	view →
LIHC	OS	Median	II,III,IV	0.198	0.719	.003	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ALG1L2–UCEC (DFS)

Open the UCEC breakdown →